REFERENCES
1. El-Brolosy MA, Kontarakis Z, Rossi A, et al. Genetic compensation triggered by mutant mRNA degradation. Nature. 2019;568:193-7.
2. Kontarakis Z, Stainier DYR. Genetics in light of transcriptional adaptation. Trends Genet. 2020;36:926-35.
3. Serobyan V, Kontarakis Z, El-Brolosy MA, et al. Transcriptional adaptation in Caenorhabditis elegans. ELife. 2020;9:e50014.
4. Rossi A, Kontarakis Z, Gerri C, et al. Genetic compensation induced by deleterious mutations but not gene knockdowns. Nature. 2015;524:230-3.
5. Ma Z, Zhu P, Shi H, et al. PTC-bearing mRNA elicits a genetic compensation response via Upf3a and COMPASS components. Nature. 2019;568:259-63.
6. Falcucci L, Dooley CM, Adamoski D, et al. Transcriptional adaptation upregulates utrophin in Duchenne muscular dystrophy. Nature. 2025;639:493-502.
7. Ralu M, Guiraud S, Dastidar S, et al. CRISPR-Cas9-mediated upregulation of utrophin ameliorates Duchenne muscular dystrophy. Mol Ther. 2026;34:3903-23.
8. Vaillend C, Aoki Y, Mercuri E, et al. Duchenne muscular dystrophy: recent insights in brain related comorbidities. Nat Commun. 2025;16:1298.
9. Mendell JR, Muntoni F, McDonald CM, et al. AAV gene therapy for Duchenne muscular dystrophy: the EMBARK phase 3 randomized trial. Nat Med. 2025;31:332-41.
10. Roberts TC, Wood MJA, Davies KE. Therapeutic approaches for Duchenne muscular dystrophy. Nat Rev Drug Discov. 2023;22:917-34.
11. Wu R, Li P, Xiao P, et al. Activation of endogenous full-length utrophin by MyoAAV-UA as a therapeutic approach for Duchenne muscular dystrophy. Nat Commun. 2025;16:2398.
12. Masubuchi N, Shidoh Y, Kondo S, Takatoh J, Hanaoka K. Subcellular localization of dystrophin isoforms in cardiomyocytes and phenotypic analysis of dystrophin-deficient mice reveal cardiac myopathy is predominantly caused by a deficiency in full-length dystrophin. Exp Anim. 2013;62:211-7.
13. Long C, Amoasii L, Bassel-Duby R, Olson EN. Genome editing of monogenic neuromuscular diseases: a systematic review. JAMA Neurol. 2016;73:1349-55.
14. Mellis IA, Melzer ME, Bodkin N, Goyal Y. Prevalence of and gene regulatory constraints on transcriptional adaptation in single cells. Genome Biol. 2024;25:217.
15. Xie L, Jakutis G, Dooley CM, et al. Induction of a transcriptional adaptation response by RNA destabilization events. EMBO Rep. 2025;26:2262-79.
16. O’Brien S, Fujimoto M, Lowe A, Berger A. Abstract 5916: Transcriptional adaptation among highly essential paralogs contributes to genetic robustness of cancer genomes. Cancer Res. 2026;86:5916.
17. Tuffery-Giraud S, Béroud C, Leturcq F, et al. Genotype-phenotype analysis in 2,405 patients with a dystrophinopathy using the UMD-DMD database: a model of nationwide knowledgebase. Hum Mutat. 2009;30:934-45.
18. Tinsley JM, Potter AC, Phelps SR, Fisher R, Trickett JI, Davies KE. Amelioration of the dystrophic phenotype of mdx mice using a truncated utrophin transgene. Nature. 1996;384:349-53.
19. Sengupta K, Loro E, Khurana TS. PMO-based let-7c site blocking oligonucleotide (SBO) mediated utrophin upregulation in mdx mice, a therapeutic approach for Duchenne muscular dystrophy (DMD). Sci Rep. 2020;10:21492.
20. Clerk A, Morris GE, Dubowitz V, Davies KE, Sewry CA. Dystrophin-related protein, utrophin, in normal and dystrophic human fetal skeletal muscle. Histochem J. 1993;25:554-61.
21. Helliwell TR, Man NT, Morris GE, Davies KE. The dystrophin-related protein, utrophin, is expressed on the sarcolemma of regenerating human skeletal muscle fibres in dystrophies and inflammatory myopathies. Neuromuscul Disord. 1992;2:177-84.
22. Wu R, Song Y, Wu S, Chen Y. Promising therapeutic approaches of utrophin replacing dystrophin in the treatment of Duchenne muscular dystrophy. Fundam Res. 2022;2:885-93.
23. Kawajiri M, Mitsui T, Kawai H, Kobunai T, Tsuchihashi T, Saito S. Dystrophin, utrophin and β-dystroglyoan expression in skeletal muscle from patients with Becker muscular dystrophy. J Neuropathol Exp Neurol. 1996;55:896-903.
24. Tinsley J, Deconinck N, Fisher R, et al. Expression of full-length utrophin prevents muscular dystrophy in mdx mice. Nat Med. 1998;4:1441-4.
25. Ather S, Wang W, Wang Q, Li N, Anderson ME, Wehrens XH. Inhibition of CaMKII phosphorylation of RyR2 prevents inducible ventricular arrhythmias in mice with Duchenne muscular dystrophy. Heart Rhythm. 2013;10:592-9.
26. Wang Q, Wang W, Wang G, Rodney GG, Wehrens XH. Crosstalk between RyR2 oxidation and phosphorylation contributes to cardiac dysfunction in mice with Duchenne muscular dystrophy. J Mol Cell Cardiol. 2015;89:177-84.
27. Himelman E, Lillo MA, Nouet J, et al. Prevention of connexin-43 remodeling protects against Duchenne muscular dystrophy cardiomyopathy. J Clin Invest. 2020;130:1713-27.
28. Himelman E, Nouet J, Lillo MA, et al. A microtubule-connexin-43 regulatory link suppresses arrhythmias and cardiac fibrosis in Duchenne muscular dystrophy mice. Am J Physiol Heart Circ Physiol. 2022;323:H983-95.
29. Squire S, Raymackers JM, Vandebrouck C, et al. Prevention of pathology in mdx mice by expression of utrophin: analysis using an inducible transgenic expression system. Hum Mol Genet. 2002;11:3333-44.
30. Tabary M, Wehrens XHT. Advancing cardiac monitoring in adult Duchenne muscular dystrophy: longitudinal insights and real-world challenges. Int J Cardiol Heart Vasc. 2026;62:101867.
31. Juvik B, Falcucci L, Lundegaard PR, Stainier DYR. A new hypothesis to explain disease dominance. Trends Genet. 2025;41:187-93.
32. El-Brolosy MA, Oak A, Hoang AT, et al. Mechanisms linking cytoplasmic decay of translation-defective mRNA to transcriptional adaptation. Science. 2026;391:eaea1272.
33. Rossi R, Aartsma-Rus A, Muntoni F, Goyenvalle A, Spitali P. The complexity of dystrophin transcription and processing: implications of transcript imbalance on dystrophin gene targeting strategies. Neuromuscul Disord. 2026;59:106306.
